{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036163","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.017013+00:00","generated_at":"2026-05-31T11:27:09.740922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M","bullets":["Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).","GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.","GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.","Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.","Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036163","json":"https://secwatch.observer/filing/0001628280-24-036163.json","markdown":"https://secwatch.observer/filing/0001628280-24-036163.md","text":"https://secwatch.observer/filing/0001628280-24-036163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/0001628280-24-036163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/blfs-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:27:09.740922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}